Difficulty: Medium
Average Score: 73%
Practice
Early postnatal exposure to dexamethasone, within the 1st wk of life, in VLBW infants, is associated with the following EXCEPT
Correct answer
D
Rationale
In this scenario, the correct answer is D) cerebral palsy. Early postnatal exposure to dexamethasone in very low birth weight (VLBW) infants is associated with various adverse effects, such as metabolic derangements, poor growth, and an increased risk for sepsis.
Dexamethasone is a corticosteroid that, when administered in the early postnatal period, can lead to metabolic issues like hyperglycemia and hypertension. It can also negatively impact growth by affecting weight gain and bone mineralization in preterm infants. Additionally, dexamethasone can suppress the immune system, putting infants at a higher risk for sepsis.
Cerebral palsy is a neurodevelopmental disorder primarily caused by brain injury or abnormal brain development, not by dexamethasone exposure. Understanding the potential complications of dexamethasone in VLBW infants is crucial for pediatric clinical nurse specialists to provide safe and effective care. This knowledge helps in recognizing and managing the adverse effects of medications in vulnerable populations, ultimately improving patient outcomes and quality of care.
Dexamethasone is a corticosteroid that, when administered in the early postnatal period, can lead to metabolic issues like hyperglycemia and hypertension. It can also negatively impact growth by affecting weight gain and bone mineralization in preterm infants. Additionally, dexamethasone can suppress the immune system, putting infants at a higher risk for sepsis.
Cerebral palsy is a neurodevelopmental disorder primarily caused by brain injury or abnormal brain development, not by dexamethasone exposure. Understanding the potential complications of dexamethasone in VLBW infants is crucial for pediatric clinical nurse specialists to provide safe and effective care. This knowledge helps in recognizing and managing the adverse effects of medications in vulnerable populations, ultimately improving patient outcomes and quality of care.